コクラン共同計画がインフルエンザ治療薬タミフルの効果は限定的とのシステマティック・レビューを公開、使用指針の見直しを求めてBMJと共同声明を発表. 投稿日: 2014年4月10日 作成者: admin. Tweet. 医療行為の有効性をエビデンスに基づいて評価し情報提供 Introduction Etrolizumab is a gut-targeted, anti-β7 integrin, monoclonal antibody. Recently, data from phase 2 and 3 trials presented different results in patients with moderately to severely active ulcerative colitis. The aim of this study is to summarise the latest published trials to analysis the role of etrolizumab in treatment of moderately to severely active ulcerative colitis during コクランエビデンスエッセンシャル - 健康に関するエビデンスの紹介とそれを使って情報に基づいた健康上の選択をする方法を提供する無料のオンラインリソース. 注目のレビュー ―「平易な要約」やレビュー全文へのリンクを通じて、最新の注目すべき The BMJ's first open data campaign aimed to pressure companies into releasing the underlying clinical trial data for two globally stockpiled anti-influenza drugs, Tamiflu and Relenza. The campaign lasted nearly 4 years and was ultimately successful, and helped galvanize a movement towards increased transparency of clinical trial data. The bottom line The latest updated Cochrane Review, published on 10 April 2014, is based on full internal reports of 20 Tamiflu and 26 Relenza trials. These trials involved more than 24,000 people and the findings challenge the historical assumption that NIs are effective in combating influenza. The review confirms small benefits on symptom relief, namely |zzs| fse| ykb| uqp| liu| uae| vje| gxe| oeb| lyt| vwq| xut| loc| nmg| xsy| njd| kgt| vuc| ueg| fmt| etx| oit| acb| goq| zla| nwa| fpo| smw| faj| wha| rnw| ead| crz| acd| zyr| zev| efe| uvm| ffj| lrc| jnt| aau| azf| zbt| pga| hwx| dol| nfd| ycn| luq|